ImmunityBio, Inc. (IBRX) witnessed a significant pre-market surge of 5.23% on Friday, driven by investor enthusiasm over the company's plans to submit multiple treatments for approval by the U.S. Food and Drug Administration (FDA) in 2025.
The biopharmaceutical company announced that it would file a supplemental biologics license application (BLA) for the treatment of bladder cancer. If approved by the FDA, this BLA would allow ImmunityBio to commercialize its product across the United States.
Additionally, the company aims to submit another BLA for the treatment of a specific type of lung cancer. Investors were further encouraged by the positive results from a Phase 2B study, which demonstrated the efficacy of ImmunityBio's Anktiva drug in combination with other inhibitors for patients who had failed first and second-line treatment attempts.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。